This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Compugen's CGEN-15001 Pre-Clinical Data Presented At International Conference On Immune Tolerance

Compugen Ltd. (NASDAQ: CGEN), announced today that CGEN-15001 was the subject of a presentation by Joseph Podojil, Ph.D. of the Feinberg School of Medicine Northwestern University, at the 2nd International Conference on Immune Tolerance, now being held in Amsterdam. This is the first time that scientific information related to CGEN-15001's therapeutic potential is being presented to the scientific community. In his talk, Dr. Podojil presented data demonstrating that administration of CGEN-15001 in the experimental autoimmune encephalitis (EAE) animal model of multiple sclerosis (MS) resulted in a dramatic improvement of disease symptoms and abolishment of spontaneous relapses. In addition, the study results demonstrated that short-term treatment with CGEN-15001 lead to long-term inhibition of disease symptoms as well as of the underlying spread of pathological immune responses.

Dr. Podojil, a Research Assistant Professor in the laboratory of Professor Stephen Miller at Northwestern University, showed that CGEN-15001 appears to exert its beneficial therapeutic effect by modulating the immune system and preventing infiltration of reactive immune T cells into the central nervous system. CGEN-15001 thereby inhibits the underlying mechanisms which cause the debilitating disease symptoms and its relapsing nature. Similar beneficial effects were observed in two MS models, an EAE model actively induced by immunization with a myelin antigen and an adoptive transfer EAE model created by injection of immune cells specifically reactive to myelin. The results reported are from studies performed under an agreement with Northwestern University and Prof. Miller, a leading scientist in the fields of immunology and autoimmune diseases who supervised the studies.

In his talk, Dr. Podojil presented data demonstrating that the effects of CGEN-15001 include modulating the activity of a sub-group of white blood cells called T helper cells, which are known to provide signals for orchestrating the immune response. In particular, CGEN-15001 inhibits the pro-inflammatory T helper cells Th1 and Th17, while at the same time promoting anti-inflammatory Th2 responses. T cell modulation can be therapeutically beneficial in the treatment of T cell mediated autoimmune diseases.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs